Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Dasiglucagon Micro-doses in T1D
NCT02916251Phase 2Completed
- Sponsor
- Zealand Pharma
- Start
- Dec 2016
- Primary completion
- Apr 2017
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dasiglucagon in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Zealand Pharma. Primary endpoints: Area Under the Curve 0-240 min, Maximum Plasma Concentration and 4 more. Started Dec 2016; status: completed.
02
Drugs
dasiglucagon
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02916251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02916251.